Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Total Liabilities (2019 - 2025)

Maxcyte (MXCT) has disclosed Total Liabilities for 7 consecutive years, with $31.0 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 6.63% to $31.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $31.0 million through Dec 2025, down 6.63% year-over-year, with the annual reading at $31.0 million for FY2025, 6.63% down from the prior year.
  • Total Liabilities for Q4 2025 was $31.0 million at Maxcyte, down from $33.2 million in the prior quarter.
  • The five-year high for Total Liabilities was $36.1 million in Q4 2023, with the low at -$81.3 million in Q1 2021.
  • Average Total Liabilities over 5 years is $24.1 million, with a median of $31.3 million recorded in 2024.
  • The sharpest move saw Total Liabilities skyrocketed 138.79% in 2021, then decreased 8.0% in 2024.
  • Over 5 years, Total Liabilities stood at $21.2 million in 2021, then skyrocketed by 54.01% to $32.7 million in 2022, then rose by 10.47% to $36.1 million in 2023, then fell by 8.0% to $33.2 million in 2024, then decreased by 6.63% to $31.0 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $31.0 million, $33.2 million, and $29.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.